BioSyent Posts 23% Revenue Growth in 2025, Expands via Oral Science Acquisition
Event summary
- BioSyent reported CAD 43.1M in total revenue for 2025, up 23% YoY, with international pharma sales surging 302% to CAD 3.7M.
- Q4 2025 revenue grew 10% YoY to CAD 9.7M, driven by 240% increase in international Tibelia® sales.
- Completed acquisition of Oral Science Inc. on March 2, 2026, expanding into specialized dental hygiene products.
- Increased quarterly dividend by 10% to CAD 0.055 per share, marking 62 consecutive profitable quarters.
- Repurchased 19,500 common shares under NCIB, maintaining strong balance sheet with 24% return on average equity.
The big picture
BioSyent's 23% revenue growth in 2025 reflects successful international expansion of its Tibelia® product line, complementing its legacy Canadian pharmaceutical business. The Oral Science acquisition signals a strategic pivot into oral health, diversifying its product portfolio while maintaining capital-light operations. The company's consistent profitability and disciplined capital allocation position it favorably in the specialty healthcare sector.
What we're watching
- Integration Challenges
- How BioSyent will integrate Oral Science's dental hygiene business with its existing pharmaceutical operations.
- International Growth
- Whether the 302% YoY surge in international pharma sales can be sustained through 2026.
- Capital Deployment
- The pace at which BioSyent will continue share buybacks and dividends while funding growth initiatives.
Related topics